CPT code 86825 represents an HLA crossmatch laboratory test that assesses compatibility between donor lymphocytes and an initial recipient serum sample using non-cytotoxic methods such as flow cytometry. This assay is clinically important for transplantation and transfusion planning because it detects donor-specific antibodies and cellular interactions that predict risk of graft rejection or transfusion reactions. Nationally, accurate reporting of crossmatch testing supports clinical decision-making and appropriate billing for complex immunogenetics services.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose and service setting for CPT code 86825, along with what to expect in benchmarking and policy contexts where available. The publication covers typical reimbursement considerations for laboratory immunogenetics, common clinical scenarios prompting testing, and operational settings where the service is performed. Data not available in the input includes detailed payer-specific reimbursement rates, associated taxonomies, and ICD-10 diagnoses. The piece is intended as a national-level reference on the clinical and billing identity of CPT code 86825.